Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Why Is Semaglutide Difficult to Characterize
Patients currently using these drugs may need re-evaluation by their doctors to continue qualifying for coverage
Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
The study was funded by Novo Nordisk, the manufacturer of semaglutide, and several authors are employees of the company
US$ 27.31
US$ 26.82
US$ 20.72
US$ 27.87
